2.1 CEO Report
The Board reviewed and discussed the key aspects of the CEO monthly report. The Board noted that this was the first report in the new format of the new current CEO and welcomed the approach. The Board made suggestions in relation to the new format, proposing that the order of contents should focus in order on priorities/strategic objectives, significant issues for note, Board related matters and CEO engagements. The Board also suggested that the report addresses key performance issues linked to the Board Strategic Scorecard.
The CEO reported on recent activity under the headings of access to care and urgent care and significant items of note since the last Board meeting;
Waiting List Action Plan (WLAP)
The CEO noted that an extensive Waiting List Action Plan (WLAP) for 2023 is underway as part of a multi annual approach to waiting lists for key services. This is a Department approved plan with specific oversight and engagement between Department officials and executive senior managers connected to a further process of oversight by the Minister for Health, Secretary General and CEO.
The Board were informed that while access across the organisation in all of its functions remains a challenge and key focus, the WLAP targets specific services in the hospital and to a smaller degree in the community space. In respect of the main part of the plan the CEO noted that he has now reorganised national resources to point to a single line of planning and accountability.
The Board welcomed that performance against the plan at the end of March 2023 is positive and noted that some challenges remain. The CEO informed the Board that the challenges could be grouped under three specific headings of new additions, performance against plan and additional WLAP activity. It was noted, however, that significant traction has been gained in recent weeks. The Board discussed the challenges, noting that the core to understanding performance of ‘WLAP and Access’ is the length of time people are waiting and plans to address them, including long term reforms to modernisation patient care path ways to deliver sustained meaningful reductions in waiting lists.
The Board also discussed the progress of the enhanced Community Care Program in particular the development of Community Health Care Networks which will provide for the integration of General Practice with wider community services allowing for more local decision making and improving access to primary care services.
Urgent care
The Board were informed that services continue to be challenged in respect of urgent care and that sustained focus over recent weekends was required in order to maintain a manageable position. The CEO noted that on April 20th, the trolley waiting position 363 was at 20% higher than the same day in 2022 and that, while focus on delayed transfer of care is starting to show improvement in recent weeks, it cannot be relied on as a sustainable improvement until further performance and actions are assessed. The CEO briefed the Board on the After-Action Review of Winter 2022 which was shared with the Board prior to the meeting. The Board noted that it sets good context and analysis of performance for the period, but that building Capacity will remain challenging and the only short-term improvement space is in both process and culture. The Board welcomed that the organisation focus for the balance of 2023 will remain on capacity management and for 2024 a full year-round plan as distinct from a Winter Plan will be required. It was agreed that there would be early engagement with the Performance and Planning Committee on progress and development and on the longer term recommendations to be considered as part of the development of the 3-year Unscheduled Care plan.
Organisation Change
The CEO also reported and provided an update to the Board on three key activities under in relation to organisational change:
- Establishment and first engagement with the new interim Senior Leadership Team
- The RHA draft documentation previously viewed by the Board which has now received Ministerial input and feedback. The CEO also noted that all resource and activity on RHA development and Centre design to one single point of accountability are now directly within the scope of his office.
- Ongoing work with the Technology and Transformation Committee regarding the framework for understanding and managing all change activity. The Board noted that the outcome of this work will be considered at the May Board meeting.
HR position
It was noted that the HR position remains as last notified, with good outturn on recruitment but that significant work is yet to be advanced in both resourcing and the overall approach to a People Strategy Performance.
Significant issues for noting
The CEO advised the Board on the following service-related issues for noting at this time, given recent or pending attention to them:
- Progressing Disability Services and Assessment of Need Disability
- Termination Services Review – recommendations from report to be circulated to Board
- Paediatric Palliative Care
- Clinical Focus
- Public Accounts Committee
- Capital Plan revised – proposed changes to be circulated for Board approval.
2.2 Financial Matters
The CFO was in attendance for the discussion of this item. The Board noted the 2023 Revised Approved Level of Expenditure (Letter of Determination) dated 06 April 2023, and the two specific financial concerns which related to the level of emerging expenditure trajectory, specifically in relation to the COVID Acute and Community responses particularly with regard to the unfunded and once-off only funding nature of expenditure, and the already evident expenditure pressures within the hospital system. The Board continued to highlight their concern in relation to the overall level of financial issues and risks, outlined in the National Service Plan of up to 10.2% (or €2.2bn) that may arise in 2023.
The CFO outlined to the Board the four spend categories to which the HSE will experience financial issues and risks during 2023. He advised that the DOH have indicated that, in their view, the HSE figures overstate the level of financial issues and risks, but that the DOH and HSE are fully aligned on the need for any mitigation measures relating to addressing the financial issues and risks will not impact negatively on planned service capacity, activity or access.
The Board were advised in relation to the approach and key principles of the Financial Framework which are: to provide services with realistic budgets, to report and monitor any deviation in deficits arising under the relevant spend categories and the mitigation actions and expenditure management programme that are in place, and will be updated as necessary in light of experience and engagement as the year progresses.
The Board discussed the financial position at the end of February 2023, noting the overall core deficit of €126.9m, with acute operations represented as 165% of the total YTD Feb deficit and COVID – 19 at 69%.
They noted that in advance of the availability of the preliminary 2023 Financial Outlook based on Q1 results, initial indications are an I&E 2023 deficit in the region of circa €1.6b with a cash shortfall of circa €1.1b, which compares to the €2.2b (10.2%) flagged in the National Service Plan 2023. The CFO advised the Board that this assessment is heavily caveated and can only be used as an initial indicator of potential in expenditure for 2023. The CEO advised the Board that the financial information will be better informed when the Q1 figures are finalised, and will be brought to the Board at their meeting in May 2023.
The CFO advised the Board that ongoing engagement with external stakeholders including the DoH, via the Health Budget Oversight Group process, is continuing, and that critical focus in the challenging financial position remains.
The Board recognised the impact that the financial challenge will have on available resources and delivery of services, and highlighted that the HSE will need to work collectively with significant monitoring and engagement through internal governance structures, most notably through the EMT, Audit and Risk Committee and the Board.
2.3 Board Strategic Scorecard 2023
The CSO, CFO, COO, CCO, ND HR were in attendance for the discussion of this item. The CEO presented the April Board Strategic Scorecard (BSS) 2023 for the March reporting period, as circulated prior to the meeting. The Board noted that due to the timing of the Board meetings, the absence of comprehensive integrated information systems and other factors, it is not possible for the CEO to present the BSS to the Board in a manner consistent with the timelines for the submission of Board papers, therefore the BSS is presented to the Board with 62% of KPI’s profiled.
The Board and CEO discussed various ways that the BSS could be presented to ensure that an adequate and complete review is possible.
It was agreed that, going forward, the BSS will be presented to the Board two months in arrears, with the March reporting period being presented at the May Board meeting, to ensure that all of the information necessary for the completed BSS is included. The Board requested that if there are any issues with the more present data, that the CEO will advise the Board in his CEO Report.
The Board also agreed that a more detailed consideration of the BSS would be reviewed by the Board each quarter.
It was agreed to defer the approval of the BSS presented at today’s Board meeting, and that the CSO would forward a copy of the BSS to the Department of Health.